Cellect Biotechnology (APOP) Getting Somewhat Favorable News Coverage, Study Finds
Media coverage about Cellect Biotechnology (NASDAQ:APOP) has trended somewhat positive recently, Accern Sentiment reports. The research group identifies positive and negative press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Cellect Biotechnology earned a news impact score of 0.05 on Accern’s scale. Accern also assigned news articles about the company an impact score of 46.1911147740188 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
A number of analysts have recently commented on APOP shares. ValuEngine cut Cellect Biotechnology from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. HC Wainwright reiterated a “buy” rating and set a $14.00 target price (up previously from $12.00) on shares of Cellect Biotechnology in a research report on Monday, September 25th.
Cellect Biotechnology (NASDAQ APOP) opened at $6.92 on Friday. Cellect Biotechnology has a twelve month low of $2.30 and a twelve month high of $13.50.
Cellect Biotechnology Company Profile
Cellect Biotechnology Ltd., a biotechnology company, focuses on developing technologies for the functional selection of stem cells in the field of regenerative medicine and stem cell therapies in Israel. It is developing the Apotainer selection kit, a shelf stem cell selection kit, based on its Powered by Cellect technology platform for allogeneic hematopoietic stem cell transplantation procedures for patients suffering from hematological malignancies.
Receive News & Ratings for Cellect Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellect Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.